Comprehensive review of the epidemiology and treatments for malignant adult cardiac tumors

Taguchi, Shinichi

doi:10.1007/s11748-018-0912-3

Cited by 47 publications

(42 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, the regenerative capacity of cardiomyocytes is considered to be negligibly low. Thus, cardiomyocytes appear to resist further transformation and proliferation processes such as EMT in the development of cancer (92). Accordingly, signaling of TGFβ in fibrogenesis of the heart might not be identical to that occurring in other organs where progressive fibrosis ultimately develops cancers.…”

Section: Tgf-β Signaling In the Development Of Cancersmentioning

confidence: 99%

Therapeutic Targets for the Treatment of Cardiac Fibrosis and Cancer: Focusing on TGF-β Signaling

Parichatikanond

Luangmonkong

Mangmool

et al. 2020

Front. Cardiovasc. Med.

106

View full text Add to dashboard Cite

Transforming growth factor-β (TGF-β) is a common mediator of cancer progression and fibrosis. Fibrosis can be a significant pathology in multiple organs, including the heart. In this review, we explain how inhibitors of TGF-β signaling can work as antifibrotic therapy. After cardiac injury, profibrotic mediators such as TGF-β, angiotensin II, and endothelin-1 simultaneously activate cardiac fibroblasts, resulting in fibroblast proliferation and migration, deposition of extracellular matrix proteins, and myofibroblast differentiation, which ultimately lead to the development of cardiac fibrosis. The consequences of fibrosis include a wide range of cardiac disorders, including contractile dysfunction, distortion of the cardiac structure, cardiac remodeling, and heart failure. Among various molecular contributors, TGF-β and its signaling pathways which play a major role in carcinogenesis are considered master fibrotic mediators. In fact, recently the inhibition of TGF-β signaling pathways using small molecule inhibitors, antibodies, and gene deletion has shown that the progression of several cancer types was suppressed. Therefore, inhibitors of TGF-β signaling are promising targets for the treatment of tissue fibrosis and cancers. In this review, we discuss the molecular mechanisms of TGF-β in the pathogenesis of cardiac fibrosis and cancer. We will review recent in vitro and in vivo evidence regarding antifibrotic and anticancer actions of TGF-β inhibitors. In addition, we also present available clinical data on therapy based on inhibiting TGF-β signaling for the treatment of cancers and cardiac fibrosis.

show abstract

Section: Tgf-β Signaling In the Development Of Cancersmentioning

confidence: 99%

Therapeutic Targets for the Treatment of Cardiac Fibrosis and Cancer: Focusing on TGF-β Signaling

Parichatikanond

Luangmonkong

Mangmool

et al. 2020

Front. Cardiovasc. Med.

106

View full text Add to dashboard Cite

show abstract

“…Surgical resection of metastases to the heart is indicated in patients who not only show symptoms of intracardiac obstruction but also have a favorable prognosis. Some types of metastatic tumors respond to radiotherapy and chemotherapy as well [10].…”

Section: Discussionmentioning

confidence: 99%

Metastatic Cancer Masquerading as Acute Coronary Syndrome

Rao

Nealy

Khan

et al. 2020

Cureus

View full text Add to dashboard Cite

Patients with heart metastases could present insidiously, with symptoms that mimic those of congestive heart failure or acute coronary syndrome. Our patient initially presented with vague lower sternal and abdominal pain and had a past medical history of coronary artery disease. Her first two troponin levels were elevated, and her EKG was significant for ischemic changes. Echocardiography showed a large mass in the right ventricle and the presence of pericardial effusion. CT scan of the thorax, abdomen, and pelvis showed multiple pulmonary nodules as well as liver metastases. Our patient opted not to pursue further imaging such as cardiac MRI or a liver biopsy. It is imperative that medical professionals are aware of the presentational overlap between acute coronary syndrome and metastatic heart disease, in order to ensure proper diagnosis and management of the latter with echocardiography, cardiac MRI, and possibly surgery.

show abstract

“…PMPM is rare. Its prevalence in a large autopsy study was less than 0.0022% [ 4 ], although it is one of the common pericardial tumors in some clinical series [ 5 ]. McGehee and colleagues recently provided review of 103 published cases [ 6 ].…”

Section: Discussionmentioning

confidence: 99%

Primary malignant pericardial mesothelioma presenting with cardiac tamponade

Matsuyama

Imazuru

Uchiyama

et al. 2020

International Journal of Surgery Case Reports

View full text Add to dashboard Cite

Highlights Primary malignant pericardial mesothelioma is rare, and its diagnosis is difficult. The surgical intervention was performed after pericardiocentesis for definitive diagnosis and treatment. The prognosis of malignant pericardial mesothelioma was very poor. The indications for surgical intervention should be carefully considered except for critical cases.

show abstract

Comprehensive review of the epidemiology and treatments for malignant adult cardiac tumors

Cited by 47 publications

References 27 publications

Therapeutic Targets for the Treatment of Cardiac Fibrosis and Cancer: Focusing on TGF-β Signaling

Therapeutic Targets for the Treatment of Cardiac Fibrosis and Cancer: Focusing on TGF-β Signaling

Metastatic Cancer Masquerading as Acute Coronary Syndrome

Primary malignant pericardial mesothelioma presenting with cardiac tamponade

Contact Info

Product

Resources

About